Can pT0 Stage of Prostate Cancer be Predicted before Radical Prostatectomy?

European Urology

Volumn 50, Issue 6, 2006, Pages 1248-1253

  Descazeaud, Aurélien ^a   Zerbib, Marc ^a   Flam, Thierry ^a   Vieillefond, Annick ^a   Debré, Bernard ^a   Peyromaure, Michaël ^a  

^a Cochin Hospital ^*  (France)

Author keywords

Pathologic analysis; Prostate cancer; pT0; Radical prostatectomy; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; INSTITUTIONAL CARE; MALE; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SURGICAL PATIENT;

AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 33750618401     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.06.004     Document Type: Article

References (11)

1. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
2. Kollermann J., Hopfenmuller W., Caprano J., et al. Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis. Eur Urol 45 (2004) 42-45
3. Kollermann J., Caprano J., Budde A., et al. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy. Urology 62 (2003) 476-480
4. Kollermann J., Feek U., Muller H., et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol 38 (2000) 714-720
5. Hammerer P. pT0 after radical prostatectomy: overtreatment for insignificant prostate cancer?. Eur Urol 45 (2004) 35
6. DiGiuseppe J.A., Sauvageot J., and Epstein J.I. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol 21 (1997) 174-178
7. Herkommer K., Kuefer R., Gschwend J.E., Hautmann R.E., and Volkmer B.G. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol 45 (2004) 36-41
8. Goldstein N.S., Begin L.R., Grody W.W., Novak J.M., Qian J., and Bostwick D.G. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the "vanishing cancer phenomenon". Am J Surg Pathol 19 (1995) 1002-1009
9. Bostwick D.G., and Bostwick K.C. 'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int 94 (2004) 57-58
10. Cao D., Hafez M., Berg K., Murphy K., and Epstein J.I. Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen? A microsatellite analysis of specimen identity. Am J Surg Pathol 29 (2005) 467-473
11. Descazeaud A., Rubin M.A., Allory Y., et al. What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?. Eur Urol 48 (2005) 911-915